Rhythm expands obesity portfolio with Phase II weight loss drug for $100m

Rhythm Pharmaceuticals has entered a global licensing agreement with South Korea-based LG Chem for the latter’s weight loss drug LB54640, which is currently in Phase II clinical development.

Rhythm will pay $40m in cash and $20m in equity at deal closing, as per a 4 January press release.